<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423747</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-SZT- BFM 2003</org_study_id>
    <nct_id>NCT01423747</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anna Kinderkrebsforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International BFM Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Anna Kinderkrebsforschung</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this protocol the ALL-SZT BFM international study group wants

      to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or
      unrelated matched donors (MD) is equivalent to the HSCT from matched sibling donors (MSD).

      to evaluate the efficacy of haematopoietic stem cell transplantation (HSCT) from mismatched
      family or unrelated mismatched donors (MMD) as compared to HSCT from matched sibling donor
      (MSD) and matched donor (MD).

      to determine whether therapy has been carried out according to the main haematopoietic stem
      cell transplantation (HSCT) protocol recommendations. The standardisation of the treatment
      options during haematopoietic stem cell transplantation (HSCT) from different donor types
      aims at the achievement of an optimal comparison of survival after HSCT with survival after
      chemotherapy only.

      to prospectively evaluate and compare the incidence of acute and chronic graft-
      versus-host-disease (GvHD) after haematopoietic stem cell transplantation (HSCT) from matched
      sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with high risk or relapsed acute lymphoblastic leukaemia (ALL) have a worse
      prognosis compared to all other patients with ALL. For these patients additional therapy
      approaches are required after they have achieved remission with multimodal chemotherapy.
      Allogeneic haematopoetic stem cell transplantation shows promising results mainly due to an
      immunological antileukaemic control by the graft-versus-leukaemia effect, but treatment
      related mortality and morbidity remains a serious problem.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2003</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free and overall survival after allogeneic haematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>14 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of acute and chronic Graft-versus-Host-Disease (GvHD)</measure>
    <time_frame>14 years</time_frame>
    <description>Evaluation of the incidence and severity of acute Grade I-IV Graft-versus-Host-Disease (GvHD) and of limited or extensive chronic GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of late effects after chemotherapy with subsequent allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>14 years</time_frame>
    <description>valuation of organ dysfunctions according to WHO Toxicity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of late effects after chemotherapy with subsequent allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>14</time_frame>
    <description>evaluation of growth retardation and endocrine dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of late effects after chemotherapy with subsequent allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>14 years</time_frame>
    <description>Evaluation of incidence of aseptic bone necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of secondary malignancies after chemotherapy with subsequent allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>14 years</time_frame>
    <description>Evaluation of incidence of secondary cancer after total body irradiation (TBI) and/or chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lymphoblastic Leukemia, Acute, Childhood;</condition>
  <arm_group>
    <arm_group_label>MSD - matched sibling donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD - matched donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMD - mismatched Donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16</intervention_name>
    <description>patients with MSD receive as conditioning VP16 60mg/kg/d on day -3</description>
    <arm_group_label>MSD - matched sibling donor</arm_group_label>
    <other_name>Etoposid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning</description>
    <arm_group_label>MSD - matched sibling donor</arm_group_label>
    <other_name>total body irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16, ATG</intervention_name>
    <description>patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1</description>
    <arm_group_label>MD - matched donor</arm_group_label>
    <other_name>Etoposid, Antithymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)</description>
    <arm_group_label>MD - matched donor</arm_group_label>
    <other_name>total body irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, OKT3, Treosulfan, Thiotepa</intervention_name>
    <description>patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4</description>
    <arm_group_label>MMD - mismatched Donor</arm_group_label>
    <other_name>ATG:Antithymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16, ATG</intervention_name>
    <description>patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d</description>
    <arm_group_label>MMD - mismatched Donor</arm_group_label>
    <other_name>Etoposid, Antithymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions</description>
    <arm_group_label>MMD - mismatched Donor</arm_group_label>
    <other_name>total body irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age at time of initial diagnosis or relapse diagnosis, respectively under or equal 18
             years

          -  indication for allogeneic hematopoietic stem cell transplantation (HSCT)

          -  complete remission before hematopoietic stem cell transplantation (HSCT)

          -  written consent of the parents (legal guardian) and, if necessary, the minor patient
             via Informed Consent Form

          -  no pregnancy

          -  no secondary malignancy

          -  no previous hematopoietic stem cell transplantation (HSCT)

          -  hematopoietic stem cell transplantation (HSCT) is performed in a study participating
             centre.

        Exclusion Criteria:

          -  age at time of initial diagnosis or relapse diagnosis, respectively above 18 years

          -  no indication for allogeneic HSCT

          -  no complete remission before SCT

          -  no written consent of the parents (legal guardian) and, if necessary, the minor
             patient via Informed Consent Form

          -  pregnancy

          -  secondary malignancy

          -  previous HSCT

          -  HSCT is not performed in a study participating centre.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arend v. Stackelberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ALL-REZ BFM Study Center Berlin Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Schrappe, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>ALL BFM study center Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow- Klinikum, Klinikum der Pädiatrie, Onkologie/Hämatologie/KMT</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Kinderheilkunde, Hämatologie, Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik f. Kinderonkologie, Hämatologie u. Immunologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40001</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder und Jugendliche der Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Zentrum für Kinderheilkunde, Abt. für Hämatologie/Onkologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinderheilkunde III, Hämatologie und Onkologie, Johann Wolfgang Goethe Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Zentrum für Kinderheilkunde und Jugendmedizin, Klinik IV: Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kinderheilkunde, Abt. Hämatologie und Onkologie</name>
      <address>
        <city>Giessen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinkum der Med. Fakultät der Martin-Luther-Universität Halle-Wittenberg, Uni. Klinik un Poliklinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Kinderklinik, Abt. für Hämatologie und Onkologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover, Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskinderklinik, Päd. Hämatologie, Onkologie und Immunologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Knochenmarktransplantation</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Jena</city>
        <zip>07724</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Kiel, Klinik für Allgemeine Pädiatrie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Dr. von Haunersches Kinderspital, Abt. für Hämatologie / Onkologie</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Krankenhaus München-Schwabing, Universitätskinderklinik der TU</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik und Poliklinik für Kinderheilkunde, päd. Hämatologie / Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Kinderheilkunde und Jugendmedizin</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskinderklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik, päd. Onkologie/Stammzelltransplantation</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.stanna.at/content.php?p=1&amp;lang=de</url>
    <description>Web Site St. Anna Children's Hospital</description>
  </link>
  <results_reference>
    <citation>Peters C, Schrauder A, Schrappe M, von Stackelberg A, Stary J, Yaniv I, Gadner H, Klingebiel T; BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant. 2005 Mar;35 Suppl 1:S9-11.</citation>
    <PMID>15812540</PMID>
  </results_reference>
  <results_reference>
    <citation>Pulsipher MA, Peters C, Pui CH. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S137-48. doi: 10.1016/j.bbmt.2010.10.005. Review.</citation>
    <PMID>21195303</PMID>
  </results_reference>
  <results_reference>
    <citation>Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015 Apr 10;33(11):1265-74. doi: 10.1200/JCO.2014.58.9747. Epub 2015 Mar 9.</citation>
    <PMID>25753432</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Anna Kinderspital, Austria</investigator_affiliation>
    <investigator_full_name>Prof. Christina Peters</investigator_full_name>
    <investigator_title>MD, PHD</investigator_title>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>HSCT</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

